ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL2103875
CHEMBL2103875
Compound Name TRAMETINIB
ChEMBL Synonyms TRAMETINIB | MEKINIST | GSK1120212B | TRAMETINIB DIMETHYL SULFOXIDE | GSK1120212
Max Phase 4 (Approved)
Trade Names MEKINIST
Molecular Formula C26H23FIN5O4

Additional synonyms for CHEMBL2103875 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(N ...
Download SMILES
Standard InChI InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10- ...
Download InChI
Standard InChI Key LIRYPHYGHXZJBZ-UHFFFAOYSA-N

Sources

  • AstraZeneca Deposited Data
  • British National Formulary
  • Orange Book
  • Patent Bioactivity Data
  • PubChem BioAssays
  • Scientific Literature
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification

Alternate Forms of Compound in ChEMBL


CHEMBL2103875

Molecule Features

CHEMBL2103875 compound icon
Drug Type:Synthetic Small Molecule Rule of Five:N First In Class:N Chirality:Achiral Molecule Prodrug:N Oral:Y Parenteral:N Topical:N Black Box:N Availability Type:Prescription-only

Mechanism of Action

Mechanism of Action ChEMBL Target References
Dual specificity mitogen-activated protein kinase kinase 1 inhibitor Dual specificity mitogen-activated protein kinase kinase 1 FDA
Dual specificity mitogen-activated protein kinase kinase 2 inhibitor Dual specificity mitogen-activated protein kinase kinase 2 FDA

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
MelanomaD008545EFO:0002617metastatic melanoma4FDA
ClinicalTrials
Pancreatic NeoplasmsD010190EFO:0002618pancreatic carcinoma1ClinicalTrials
Breast NeoplasmsD001943EFO:0000305breast carcinoma2ClinicalTrials
Multiple MyelomaD009101EFO:0001378multiple myeloma2ClinicalTrials
Thyroid NeoplasmsD013964EFO:0002892thyroid carcinoma2ClinicalTrials
Colorectal NeoplasmsD015179EFO:1001951colorectal carcinoma2ClinicalTrials
Mouth NeoplasmsD009062EFO:0003868mouth neoplasm2ClinicalTrials
NeoplasmsD009369EFO:0000616neoplasm4ATC
ClinicalTrials
Carcinoma, Non-Small-Cell LungD002289EFO:0003060non-small cell lung carcinoma2ClinicalTrials
Adenocarcinoma, FollicularD018263EFO:0000501follicular thyroid carcinoma2ClinicalTrials
Gastrointestinal Stromal TumorsD046152Orphanet:44890Gastrointestinal stromal tumor2ClinicalTrials
Leukemia, Myeloid, AcuteD015470EFO:0000222acute myeloid leukemia2ClinicalTrials
Prostatic NeoplasmsD011471EFO:0000196metastatic prostate cancer2ClinicalTrials
Thyroid NeoplasmsD013964EFO:0000641papillary thyroid carcinoma2ClinicalTrials
Erdheim-Chester DiseaseD031249EFO:1000926Erdheim-Chester disease2ClinicalTrials
MelanomaD008545EFO:0000389cutaneous melanoma3ClinicalTrials
NeoplasmsD009369EFO:0000311cancer4ClinicalTrials
ClinicalTrials
Rectal NeoplasmsD012004EFO:1000657rectum cancer1ClinicalTrials
LeukemiaD007938EFO:0000565leukemia1ClinicalTrials
Uterine Cervical NeoplasmsD002583EFO:0001061cervical carcinoma2ClinicalTrials
Carcinoma, HepatocellularD006528EFO:0000182hepatocellular carcinoma1ClinicalTrials
MelanomaD008545EFO:0000756melanoma3ClinicalTrials
Prostatic NeoplasmsD011471EFO:0001663prostate carcinoma2ClinicalTrials

Clinical Data

ClinicalTrials.gov TRAMETINIB
The Cochrane Collaboration TRAMETINIB

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Target Predictions

The two tables below display ChEMBL single-protein targets which are predicted to interact with CHEMBL2103875. A 1uM and 10 uM cut-off have been applied to ChEMBL bioactivity data used to generate the respective models and the yellow coloured rows correspond to genuine predictions, i.e. targets not included in the original training set for this compound.


1uM


ChEMBL_ID Target Name Organism Score
CHEMBL3587 Dual specificity mitogen-activated protein kinase kinase 1 Homo sapiens 1.000
CHEMBL2250 Tyrosine-protein kinase BLK Homo sapiens 0.733
CHEMBL260 MAP kinase p38 alpha Homo sapiens 0.644
CHEMBL4096 Cellular tumor antigen p53 Homo sapiens 0.316

10uM


ChEMBL_ID Target Name Organism Score
CHEMBL3587 Dual specificity mitogen-activated protein kinase kinase 1 Homo sapiens 1.000
CHEMBL2964 Dual specificity mitogen-activated protein kinase kinase 2 Homo sapiens 1.000
CHEMBL260 MAP kinase p38 alpha Homo sapiens 0.648
CHEMBL3834 Tyrosine-protein kinase BMX Homo sapiens 0.227

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
615.4 615.0779 3.94 5 107.13 NEUTRAL


HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
8 2 1 9 2 1


ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
- .26 2.54 2.54 4 37 0.33

Structural Alerts

There are 4 structural alerts for CHEMBL2103875. To view alerts please click here.

Compound Cross References

ATC L - ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 - ANTINEOPLASTIC AGENTS
L01X - OTHER ANTINEOPLASTIC AGENTS
L01XE - Protein kinase inhibitors
L01XE25 - trametinib

ChemSpider ChemSpider:LIRYPHYGHXZJBZ-UHFFFAOYSA-N
DailyMed trametinib dimethyl sulfoxide
PubChem SID: 137276024

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL2103875



ACToR 871700-17-3
ChEBI 75998
ChemicalBook CB32514557
DrugBank DB08911
DrugCentral 4802
eMolecules 36723803
FDA SRS 33E86K87QN
Guide to Pharmacology 6495
IBM Patent System 19912EA5A035D0882B3E6E5EC824149D
LINCS LSM-1143
MolPort MolPort-019-879-136
Nikkaji J3.135.455B
PharmGKB PA166115364
PubChem 11707110
PubChem: Thomson Pharma 117699169
Selleck gsk1120212-(jtp-74057)
SureChEMBL SCHEMBL170938
ZINC ZINC000043100709

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/LIRYPHYGHXZJBZ-UHFFFAOYSA-N spacer
spacer